FDA Approves New Large-Diameter Tapered Designs of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
W.L. Gore and Associates (GORE) announced the growth of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System after the Food and Drug Administration (FDA) approval of 4 new large diameter tapered designs: 34×28 mm, 37×31 mm, 40×34 mm and 45×37 mm.
The GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System was first FDA-approved in 2019 for endovascular repair of descending thoracic aorta, including aneurysms, transections and Type B dissections.
The first U.S. commercial use of the new large diameter tapered design was performed by Dr. Sukgu Han, Chief of the Division of Vascular Surgery and Endovascular Therapy at the University of Southern California in Los Angeles. In Gore’s press release, Dr. Han commented, “The right device sizing is always critical,” Dr. Han emphasized, “and even more so when treating in a narrow true lumen. These additional tapered designs will help us achieve optimal sizing for a broader range of aortic diameters while continuing to leverage the proven performance and properties of this device system.”
